Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,392.00
Bid: 12,376.00
Ask: 12,380.00
Change: -74.00 (-0.59%)
Spread: 4.00 (0.032%)
Open: 12,466.00
High: 12,512.00
Low: 12,330.00
Prev. Close: 12,466.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 4-With new Omicron case detected, UK awaits COVID booster advice

Sun, 28th Nov 2021 09:34

* UK wants to broaden booster campaign

* New measures are temporary

* Scotland also to introduce travel measures
(Adds third case, FT report)

By Elizabeth Piper

LONDON, Nov 28 (Reuters) - Britain's health minister Sajid
Javid said on Sunday he expected to receive advice imminently on
whether the government can broaden a booster shot programme to
try to weaken the impact of the newly identified Omicron
coronavirus variant.

A day after Britain said it had detected two cases of the
variant, its health agency recorded a third - in a person who
was linked to travel to Southern Africa but had since left the
country after spending time in the capital London.

The government announced new measures on Saturday to try to
slow the spread of the variant, toughening rules for people
arriving into Britain and ordering the use of face masks in
retail settings and on transport in England.

But ministers also want to ramp up the offer of booster
jabs, saying even if vaccines prove to be less effective against
Omicron, they should offer better protection against it and
reduce the number of hospitalisations and deaths.

"The other thing that still remains hugely important, but I
think it's fair to say now more important than it was before, is
our vaccination programme," Javid told Sky News.

"That is why I have also asked our expert advisers on
vaccines called JCVI (the Joint Committee on Vaccination and
Immunisation) to give me very quick advice on broadening,
boosting our booster programme, and I expect to get that advice
imminently."

Earlier this month, Britain expanded eligibility for booster
jabs to people in their 40s and also said children aged 16 and
17 would be able to receive a second dose following guidance
from the JCVI.

Scotland, where the government sets its own health rules,
already requires people to wear face coverings and work from
home if possible, but its first minister, Nicola Sturgeon, told
the BBC's Andrew Marr show she would also bring in new rules for
arrivals.

"I think we need to be open minded to doing anything
required to keep the population safe right now," she said.

BUYING TIME

The discovery of Omicron, dubbed a "variant of concern" last
week by the World Health Organization, has sparked worries
around the world https://www.reuters.com/world/new-coronavirus-variant-omicron-keeps-spreading-australia-detects-cases-2021-11-28
that it could resist vaccinations and prolong the nearly
two-year COVID-19 pandemic.

Javid said the new measures were needed to buy time for
experts to understand more about Omicron, which is likely to
have spread in Britain beyond the three cases so far detected.

Jenny Harries, chief executive of the UK's Health Security
Agency, said: "It is very likely that we will find more cases
over the coming days, as we are seeing in other countries
globally, and as we increase case detection through focused
contact-tracing."

The Financial Times newspaper cited people familiar with the
matter as saying public health leaders had been briefed that
among the cases being investigated is a traveller who arrived
back in the UK from South Africa on Nov. 16.

Paul Burton, chief medical officer at Moderna, said
that if a new vaccine was needed, "I think that's going to be
early 2022 before that’s really going to be available in large
quantities".

But Javid repeated it was not as yet clear whether vaccines
were less effective against the variant.

"The point is the vaccines are still going to give you more
protection than otherwise," he said. "That is why the booster
programme is so important."
(Reporting by Elizabeth Piper, Editing by Louise Heavens, Mark
Heinrich, Raissa Kasolowsky and Catherine Evans)

More News
12 Jun 2024 20:56

AstraZeneca's Farxiga approved to treat paediatric type-2 diabetes

(Alliance News) - AstraZeneca PLC on Wednesday said its Farxiga treatment has been approved in the US to treat some diabetes sufferers.

Read more
10 Jun 2024 09:10

LONDON BROKER RATINGS: JPMorgan cuts Aviva but lifts M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and on Friday:

Read more
10 Jun 2024 08:30

TOP NEWS: Astra's Tagrisso gets US priority review for lung cancer

(Alliance News) - AstraZeneca PLC on Monday celebrated a breakthrough therapy designation for its cancer drug Tagrisso, aimed at treating a form of non-small cell lung cancer.

Read more
10 Jun 2024 07:37

LONDON BRIEFING: FTSE called down amid political uncertainty in EU

(Alliance News) - Stocks in London are called to open lower on Monday, setting off the week on the backfoot, with eyes on the US Federal Reserve's latest interest rate decision.

Read more
10 Jun 2024 06:25

London pre-open: Stocks set for lower start after EU elections

(Sharecast News) - Stocks in London look primed for a lower start as investors digest the gains made by far right parties in Austria, Germany, but above all France, at the European Union elections that were held at the weekend.

Read more
5 Jun 2024 09:52

LONDON BROKER RATINGS: Berenberg raises Taylor Wimpey to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
5 Jun 2024 09:27

AstraZeneca completes USD2.4 billion Fusion Pharmaceuticals purchase

(Alliance News) - AstraZeneca PLC on Wednesday said it successfully completed the acquisition of Boston, Massachusetts-based Fusion Pharmaceuticals Inc.

Read more
3 Jun 2024 08:59

AstraZeneca cancer treatment Tagrisso recommended for approval in EU

(Alliance News) - AstraZeneca PLC said that, following further positive findings in clinical trial, Tagrisso has been recommended for use in the European Union.

Read more
3 Jun 2024 07:28

AstraZeneca's lung cancer treatment recommended for approval in EU

(Sharecast News) - AstraZeneca has announced that its Tagrisso treatment for advanced lung cancer, when combined with chemotherapy, has been recommended for approval by European regulators.

Read more
2 Jun 2024 20:03

Astra's Enhertu breast cancer trial shows 'unprecedented' results

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy - even if they had very low levels of the mutant protein targeted by the drug, according to trial results announced on Sunday.

Read more
2 Jun 2024 15:58

Astra's Enhertu delays breast cancer in patients with low HER2 levels

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu was shown in a large trial to delay the growth of hormone-sensitive breast cancer by about five months for people with low levels of HER2 protein whose cancer progressed following endocrine therapy, according to research presented on Sunday.

Read more
30 May 2024 09:23

LONDON BROKER RATINGS: Jefferies and UBS cut Anglo American

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:

Read more
30 May 2024 07:40

LONDON BRIEFING: Dr Martens cuts payout as profit plummets

(Alliance News) - Stocks in London are called to open lower on Thursday, with investors nervous ahead of Friday's US inflation print.

Read more
29 May 2024 08:54

IN BRIEF: AstraZeneca drug lowers cholesterol in phase 1 trial

AstraZeneca PLC - Cambridge, England-based pharmaceuticals - Reports positive results in a phase 1 trial of cholesterol drug candidate AZD0780, an oral small molecule PCSK9 inhibitor. Administered on top of rosuvastatin treatment, AZD0780 showed a statistically significant reduction in low-density lipoprotein cholesterol in plasma for test participants with hypercholesterolaemia, Astra says, while no serious adverse events were reported. "Elevated LDL-C levels in plasma is a key risk factor for cardiovascular disease and is estimated to cause 2.6 million deaths worldwide annually," Astra notes.

Read more
28 May 2024 07:02

AstraZeneca experimental lung cancer drug shows promising results

(Sharecast News) - AstraZeneca's experimental lung cancer drug showed improved overall survival rates in phase III trials, the pharmaceutical giant said on Tuesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.